255 related articles for article (PubMed ID: 25986785)
21. Cytokines for the treatment of thrombocytopenia.
Ciurea SO; Hoffman R
Semin Hematol; 2007 Jul; 44(3):166-82. PubMed ID: 17631181
[TBL] [Abstract][Full Text] [Related]
22. Recombinant human thrombopoietin in myelosuppressive chemotherapy.
Vadhan-Raj S
Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):35-8. PubMed ID: 11497230
[TBL] [Abstract][Full Text] [Related]
23. Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis.
Machlus KR; Wu SK; Vijey P; Soussou TS; Liu ZJ; Shacham E; Unger TJ; Kashyap T; Klebanov B; Sola-Visner M; Crochiere M; Italiano JE; Landesman Y
Blood; 2017 Aug; 130(9):1132-1143. PubMed ID: 28630120
[TBL] [Abstract][Full Text] [Related]
24. Platelet growth factors: potential impact on transfusion medicine.
Kuter DJ; Cebon J; Harker LA; Petz LD; McCullough J
Transfusion; 1999 Mar; 39(3):321-32. PubMed ID: 10204598
[No Abstract] [Full Text] [Related]
25. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease.
Michelson AD; Smolensky Koganov E; Forde EE; Carmichael SL; Frelinger AL
J Thromb Haemost; 2018 Dec; 16(12):2515-2519. PubMed ID: 30264918
[TBL] [Abstract][Full Text] [Related]
26. Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies?
Hofmann WK; Ottmann OG; Hoelzer D
Leukemia; 1999 Jan; 13(1):14-8. PubMed ID: 10049050
[TBL] [Abstract][Full Text] [Related]
27. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer.
Vadhan-Raj S; Murray LJ; Bueso-Ramos C; Patel S; Reddy SP; Hoots WK; Johnston T; Papadopolous NE; Hittelman WN; Johnston DA; Yang TA; Paton VE; Cohen RL; Hellmann SD; Benjamin RS; Broxmeyer HE
Ann Intern Med; 1997 May; 126(9):673-81. PubMed ID: 9139552
[TBL] [Abstract][Full Text] [Related]
28. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
Tarantino MD; Bussel JB; Blanchette VS; Despotovic J; Bennett C; Raj A; Williams B; Beam D; Morales J; Rose MJ; Carpenter N; Nie K; Eisen M
Lancet; 2016 Jul; 388(10039):45-54. PubMed ID: 27103127
[TBL] [Abstract][Full Text] [Related]
29. Milestones in understanding platelet production: a historical overview.
Kuter DJ
Br J Haematol; 2014 Apr; 165(2):248-58. PubMed ID: 24528208
[TBL] [Abstract][Full Text] [Related]
30. Usefulness of thrombopoietin receptor agonists for persistent clinically relevant thrombocytopenia after allogeneic stem cell transplantation.
Bosch-Vilaseca A; García-Cadenas I; Roldán E; Novelli S; Barba P; Esquirol A; Valcárcel D; Martino R; Sierra J
Eur J Haematol; 2018 Sep; 101(3):407-414. PubMed ID: 29956377
[TBL] [Abstract][Full Text] [Related]
31. A novel approach to the evaluation of bleeding-related episodes in patients with chronic immune thrombocytopenia.
Weitz I; Sanz MA; Henry D; Schipperus M; Godeau B; Northridge K; Gleeson M; Danese M; Deuson R
Curr Med Res Opin; 2012 May; 28(5):789-96. PubMed ID: 22494019
[TBL] [Abstract][Full Text] [Related]
32. [Short-term intermittent prophylactic administration of recombinant human thrombopoietin attenuates chemotherapy-induced thrombocytopenia in lung cancer patients].
Xu YH; Cheng BJ; Lu S; Jian H; Zhou Z; Chen ZW; Ye XY
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):395-9. PubMed ID: 21875475
[TBL] [Abstract][Full Text] [Related]
33. Recombinant human thrombopoietin clinical development.
Jones DV; Ashby M; Vadhan-Raj S; Somlo G; Champlin R; Gajewski J; Hellmann S; Fyfe G
Stem Cells; 1998; 16 Suppl 2():199-206. PubMed ID: 11012192
[TBL] [Abstract][Full Text] [Related]
34. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
Kuter DJ
Eur J Haematol Suppl; 2008 Feb; (69):9-18. PubMed ID: 18211568
[TBL] [Abstract][Full Text] [Related]
35. [A clinical comparative study on treatment of severe newly diagnosed immune thrombocytopenia by recombinant human thrombopoietin combined with glucocorticoid].
Gu SY; Zhuang JL; Zou SH; Li F; Wang ZM; Cheng YF; Wang WG; Cheng ZX; Yuan L; Cheng LY; Wei Z
Zhonghua Xue Ye Xue Za Zhi; 2013 Oct; 34(10):883-6. PubMed ID: 24171964
[TBL] [Abstract][Full Text] [Related]
36. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
[TBL] [Abstract][Full Text] [Related]
37. Serum thrombopoietin level is not regulated by transcription but by the total counts of both megakaryocytes and platelets during thrombocytopenia and thrombocytosis.
Nagata Y; Shozaki Y; Nagahisa H; Nagasawa T; Abe T; Todokoro K
Thromb Haemost; 1997 May; 77(5):808-14. PubMed ID: 9184382
[TBL] [Abstract][Full Text] [Related]
38. Physiologic role of TPO in thrombopoiesis.
Miyazaki H
Stem Cells; 1996; 14 Suppl 1():133-8. PubMed ID: 11012213
[TBL] [Abstract][Full Text] [Related]
39. Eltrombopag (Promacta), a thrombopoietin receptor agonist for the treatment of thrombocytopenia: current and future considerations.
Serebruany VL; Eisert C; Sabaeva E; Makarov L
Am J Ther; 2010; 17(1):68-74. PubMed ID: 19451811
[TBL] [Abstract][Full Text] [Related]
40. Thrombopoietic agents.
Stasi R; Bosworth J; Rhodes E; Shannon MS; Willis F; Gordon-Smith EC
Blood Rev; 2010; 24(4-5):179-90. PubMed ID: 20493600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
